IGI Laboratories (IG) Submits 5th Abbreviated New Drug Application with FDA in 2011
IGI Laboratories, Inc. (NYSE: IG) today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five.
IGI President and CEO Charlie Moore commented, “We are excited to have one additional ANDA filing for 2011. We now have five ANDAs on file with the US FDA, and we are poised to deliver a strong product development performance in 2012. ANDAs are the key to the future at IGI and our development team remains focused and motivated.” The development of ANDA products has successfully been integrated into the Company’s ongoing contract services business.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
IGI President and CEO Charlie Moore commented, “We are excited to have one additional ANDA filing for 2011. We now have five ANDAs on file with the US FDA, and we are poised to deliver a strong product development performance in 2012. ANDAs are the key to the future at IGI and our development team remains focused and motivated.” The development of ANDA products has successfully been integrated into the Company’s ongoing contract services business.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Esbriet (pirfenidone) Positive GBA Assessment
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
